Behandling av depresjon

Dette dokumentet er basert på det profesjonelle dokumentet Depresjon. Referanselisten for dette dokumentet vises nedenfor.

1. Helsedirektoratet. Nasjonal retningslinje for diagnostisering og behandling av voksne med depresjon i primær- og spesialisthelsetjenesten. Sist faglig oppdatert 13. juni 2022. www.helsedirektoratet.no 
2. World Health Organization. Depression. Last updated 30 January 2020. www.who.int 
3. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119-38. PMID: 23514317 PubMed 
4. Gutiérrez-Rojas L, Porras-Segovia A, Dunne H, et al. Prevalence and correlates of major depressive disorder: a systematic review. Braz J Psychiatry. 2020 Nov-Dec;42(6):657-672. PMID: 32756809 PubMed 
5. Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017 Feb;4(2):146-158. Epub 2016 Nov 15. PMID: 27856392. PubMed 
6. Folkehelserapporten. Psykiske lidelser hos voksne. Folkehelseinstituttet. Sist oppdatert 03.12.2021. www.fhi.no 
7. Bartlett EA, Zanderigo F, Shieh D, et al. Serotonin transporter binding in major depressive disorder: impact of serotonin system anatomy. Mol Psychiatry. 2022;27(8):3417-3424. PubMed 
8. Moncrieff J, Cooper RE, Stockmann T, et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry 2022. pmid:35854107 PubMed 
9. Peng W, Chen Z, Yin L, Jia Z, Gong Q. Essential brain structural alterations in major depressive disorder: A voxel-wise meta-analysis on first episode, medication-naive patients. J Affect Disord 2016; 199: 114-23. pmid:27100056 PubMed 
10. Schmaal L, Veltman DJ, van Erp TG, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2016; 21: 806-12. pmid:26122586 PubMed 
11. Mendenhall E, Kohrt BA, Norris SA, Ndetei D, Prabhakaran D. Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. Lancet. 2017;389(10072):951-963. PubMed 
12. Pearce M, Garcia L, Abbas A, et al. Association Between Physical Activity and Risk of Depression A Systematic Review and Meta-analysis. JAMA Psychiatry 2022. pmid:35416941 PubMed 
13. Bobo WV, Yawn BP. Concise review for physicians and other clinicians: postpartum depression. Mayo Clin Proc. 2014 ;89(6):835-44. doi: 10.1016/j.mayocp.2014.01.027 DOI 
14. Okereke OI, Reynolds CF 3rd, Mischoulon D, et al. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2020 Aug 4;324(5):471-480. PMID: 32749491. PubMed 
15. Nyström MB, Neely G, Hassmén P, et al. Treating Major Depression with Physical Activity: A Systematic Overview with Recommendations. Cogn Behav Ther 2015;44:341-52. pmid:25794191 PubMed 
16. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013 12;9:CD004366. doi: 10.1002/14651858.CD004366.pub6. The Cochrane Library 
17. Wiles N, Thomas L, Turner N, et al. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for tretment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. Lancet Psychiatry 2016
18. Furukawa TA, Suganuma A, Ostinelli EG, et al. Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. Lancet Psychiatry. 2021;8(6):500-511. PMID: 33957075 PubMed 
19. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53. Journal of the American Medical Association 
20. Stone MB, Yaseen ZS, Miller BJ, et al. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ 2022; 378: e067606. pmid:35918097 PubMed 
21. Helsedirektoratet. Nasjonal faglig retningslinje om bruk av elektronkonvulsiv behandling - ECT. IS-2629. Oslo: Helsedirektoratet 2017. helsedirektoratet.no 
22. Haq AU, Sitzmann AF, Goldman ML, et al. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015;76(10):1374-1384.
23. Rhee TG, Shim SR, Forester BP, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode A Systematic Review and Meta-analysis. JAMA Psychiatry 2022. pmid:36260324 PubMed 
24. Aust S, Brakemeier E-L, Spies J, et al. Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Depression A Randomized Clinical Trial. JAMA Psychiatry 2022. pmid:35442431 PubMed 
25. Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. Am J Psychiatry 2016. PMID: 27113121 PubMed 
26. Karyotaki E, Riper H, Twisk J, et al. Efficacy of Self-guided Internet-Based Cognitive Behavioral Therapy in the Treatment of Depressive Symptoms: A Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017. PMID: 28241179 PubMed 
27. Karyotaki E, Efthimiou O, Miguel C, et al. Internet-Based Cognitive Behavioral Therapy for Depression A Systematic Review and Individual Patient Data Network Meta-analysis. JAMA Psychiatry 2021; 78: 361-71. pmid:33471111 PubMed 
28. Legeforeningen. Gjør kloke valg. Anbefalinger. Siden besøkt 11.02.2021 www.legeforeningen.no 
29. Wiles N, Thomas L, Abel A, et al. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial. Health Technol Assess. 2014 May;18(31):1-168. PubMed 
30. Cuijpers P, Oud M, Karyotaki E et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Ann Fam Med. 2021 May-Jun;19(3):262-270. PMID: 34180847.
31. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. e-pub. The Lancet 2018. doi:https://doi.org/10.1016/S0140-6736(17)32802-7
32. Magni LR, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2013; 7: CD004185. pmid:24353997 PubMed 
33. Breedvelt JJF, Warren FC, Segal Z, et al. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression An Individual Participant Data Meta-analysis. JAMA Psychiatry 2021; 78: 868-75. pmid:34009273 PubMed 
34. Kovich H, Kim W, Quaste AM. Pharmacologic Treatment of Depression. Am Fam Physician. 2023;107(2):173-181. PubMed 
35. Henssler J, Alexander D, Schwarzer G, et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry 2022. PMID: 35171215 PubMed 
36. Hollinghurst S, Carroll FE, Abel A, et al. Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. Br J Psychiatry. 2014; 204: 69-76. PMID: 24262818 PubMed 
37. Cipriani A, Smith K, Burgess S et al. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev, issue 4, 2006. The Cochrane Library 
38. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58. PubMed 
39. NICE Guideline. Depression in adults: recognition and management. Published 29 June 2022. www.nice.org.uk 
40. Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2015. doi:10.1038/mp.2015.53 DOI 
41. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010: 167: 281-8.
42. Brent D, Emslie G, Clarke G et al. The TORDIA Randomized Controlled Trial. Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression. JAMA 2008; 299: 901-13. PubMed 
43. Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database of Systematic Reviews 2018, Issue 8. Art. No.: CD003944. DOI: 10.1002/14651858.CD003944.pub2. DOI 
44. Rink L, Braun C, Bschor T, Henssler J, Franklin J, Baethge C. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry. 2018;79(3):17r11693.
45. Lagerberg T, Fazel S, Sjölander A, Hellner C, Lichtenstein P, Chang Z. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology. 2022;47(4):817-823. PubMed 
46. Schjøtt J, Jahnsen JA. Venlafaksin og risiko for kardiovaskulære bivirkninger. Relis.no. Publisert 25.05.2016 relis.no 
47. Szegedi A, Jansen WT, van Willingenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a metaanalysis including 6562 pateints. J Clin Psychiatry 2009; MID:19254516.
48. Cuijpers P, Oud M, Karyotaki E, et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Ann Fam Med. 2021;19(3):262-270. PubMed 
49. Undurraga J, Baldessarini RJ. Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis. J Psychopharmacol. 2017;31(9):1184-1189. PubMed 
50. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601-609. PubMed 
51. Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ. 2015;350:h517. Published 2015 Feb 18.
52. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother. 2011;12(10):1623-1632. PubMed 
53. Kessler DS, MacNeill SJ, Tallon D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ. 2018. PMID: 30381374 PubMed 
54. Lunde I, Langaas HC. Vortioksetin og graviditet. RELIS 2017. relis.no 
55. Chen C, Shan W. Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis. Psychiatry Res. 2019 Nov;281:112595. Epub 2019 Oct 2. PMID: 31627074. PubMed 
56. Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014 ;348:g1888. doi: 10.1136/bmj.g1888 DOI 
57. Seifritz E, Hatzinger M, Holsboer-Trachsler E. Efficacy of Hypericum extract WS(®) 5570 compared with paroxetine in patients with a moderate major depressive episode - a subgroup analysis published correction appears in Int J Psychiatry Clin Pract. 2017 Jun;21(2):160. Int J Psychiatry Clin Pract. 2016;20(3):126-132. PubMed 
58. Maund E, Stuart B, Moore M et al. Managing Antidepressant Discontinuation: A Systematic Review. Ann Fam Med 2019; 17: 52-60. pmid:30670397 PubMed 
59. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167: 934-41. American Journal of Psychiatry 
60. Furukawa T, Streiner DL, Young LT, Kinoshita Y. Antidepressants plus benzodiazepines for major depression. Cochrane Database of Systematic Reviews, Jan 2009. CD001026. Cochrane (DOI) 
61. Edwards S, Hamilton V, Nherera L, et al. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol Assess. 2013; 54:1-190. PMID: 24284258 PubMed 
62. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646. pmid:23814104 PubMed 
63. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381-91. doi: 10.1001/jamapsychiatry.2014.1611 DOI 
64. Hallahan B, Ryan T, Hibbeln JR, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry. 2016. PMID: 27103682 PubMed 
65. Chugh S, Chhabria A, Jung S, et al. Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract, 2018; 24 (1): 15-20. pmid:29320379 PubMed 
66. Parsaik AK, Mascarenhas SS, Hashmi A, et al. Role of botulinum toxin in depression. J Psychiatr Pract, 2016; 22 (2); 99-110. pmid:27138078 PubMed 
67. Brin MF, Durgam S, Lum A, et al. OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. International Clinical Psychopharmacology 2020; 35 (1): 19-28. www.ncbi.nlm.nih.gov 
68. Dean RL, Marquardt T, Hurducas C, Spyridi S, Barnes A, Smith R, Cowen PJ, McShane R, Hawton K, Malhi GS, Geddes J, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No.: CD011611. DOI: 10.1002/14651858.CD011611.pub3. Accessed 07 November 2022 The Cochrane Library 
69. Abbar M, Dermattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ 2022; 376: e067194. pmid:35110300 PubMed 
70. Raynder L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews, April 2010. CD007503.pub2. Cochrane (DOI) 
71. Pjrek E, Friedrich ME, Cambioli L, et al. The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom. 2020;89(1):17-24. PubMed 
72. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015. doi:http://dx.doi.org/10.1136/bmj.h1798
73. Nielsen RE, Damkier P. Pharmacological treatment of unipolar depression during pregnancy and breast-feeding--a clinical overview. Nord J Psychiatry. 2012;66(3):159-166. PubMed 
74. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569. BMJ (DOI) 
75. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med;2009:163, 949-54.
76. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014; 348: f6932. BMJ (DOI) 
77. Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309: 48-54. Journal of the American Medical Association 
78. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499-07.
79. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacol. 2015 ;30:4-20. doi: 10.1002/hup.2451 DOI 
80. Coelho HF, Boddy K, Ernst E. Massage therapy for the treatment of depression: A systematic review. Int J Clin Pract 2008; 62: 325-33. PubMed 
81. Dalgaard OS. Kurs i mestring av depresjon - en randomisert, kontrollert studie. Tidsskr Nor Lægeforen 2004; 124: 3043-6. PubMed 
82. Jorm AF, Morgan AJ, Hetrick AE. Relaxation for depression. Cochrane Database of Systematic Reviews 2008; Issue 4. The Cochrane Library 
83. Kallestad H, Langsrud K, Hansen B. Søvndeprivasjon som antidepressiv behandling. Tidsskr Nor Lægeforen 2007; 127: 1360-3. PubMed 
84. Cuijpers P, van Straten A, Smit F, Mihalopoulos C. Beekman A. Preventing the onset of depressive distorders: A meta-analytic review of psychological interventions. Am J Psychiatry 2008; 165: 1272-80. American Journal of Psychiatry 
85. Segal ZV, Dimidjian S, Beck A, et al. Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms. A Randomized Clinical Trial. JAMA Psychiatry. Published online January 29, 2020. jamanetwork.com 
86. Castro A, Gili M, Ricci-Cabello I, et al. Effectiveness and adherence of telephone-administered psychotherapy for depression: A systematic review and meta-analysis. J Affect Disord. 2020;260:514-526. PubMed 
87. Mohr DC, Ho J, Duffecy J, et al. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. Telephone vs in-person therapy for depression. JAMA. 2012; 307 :2278-85.
88. Okumura Y, Ichikura K. Efficacy and acceptability of group cognitive behavioral therapy for depression: a systematic review and meta-analysis. J Affect Disord. 2014 ;164:155-64. doi: 10.1016/j.jad.2014.04.023.
89. Driessen E, Van HL, Don FJ, et al. The efficacy of cognitive-behavioral therapy and psychodynamic therapy in the outpatient treatment of major depression: A randomized clinical trial. Am J Psychiatry 2013; 170:1041-50 American Journal of Psychiatry 
90. Brunoni AR, Valiengo L, Baccaro A, et al. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry 2013; 70: 383-91. doi:10.1001/2013.jamapsychiatry.32 DOI 
91. Myhre M. Atferdsaktivering for depresjon. Tidsskrift for Norsk psykologforening 2017; 54(5): 466-471. www.psykologtidsskriftet.no 
92. Richards DA, Rhodes S, Ekers D, et al.. Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive-behavioural therapy for depression. Health Technol Assess 2017 Aug; 21(46): 1-366. pmid:28857042 PubMed 
93. Nussbaumer B, Kaminski-Hartenthaler A, Forneris CA, Morgan LC, Sonis JH, Gaynes BN, Greenblatt A, Wipplinger J, Lux LJ, Winkler D, Van Noord MG, Hofmann J, Gartlehner G. Light therapy for preventing seasonal affective disorder. Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD011269. DOI: 10.1002/14651858.CD011269.pub2 DOI 
94. Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Høie B. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Archives of Women's Mental Health, November 2013.
95. Brunoni AR, Moffa AH, Fregni F, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016. PMID: 27056623 PubMed 
96. Brunoni AR, Moffa AH, Sampaio-Junior B, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med. 2017 Jun 29;376(26):2523-33. PMID: 28657871 PubMed 
97. Berlim MT, Van den Eynde F, Daskalakis ZJ. A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychol Med. 2013;43(11):2245-54. doi: 10.1017/S0033291712002802.
98. Yesavage JA, Fairchild JK, Mi Z, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans A Randomized Clinical Trial. JAMA Psychiatry 2018. pmid:29955803 PubMed 
99. Jiang J, Zhang C, Li C, et al. Magnetic seizure therapy for treatment-resistant depression. Cochrane Database Syst Rev. 2021 Jun 16;6:CD013528. doi: 10.1002/14651858.CD013528.pub2 DOI 
100. Hamblin MR. Shining light on the head: Photobiomodulation for brain disorders. BBA Clin. 2016;6:113-124. Published 2016 Oct 1. PMID: 27752476 PubMed 
101. Salehpour F, Mahmoudi J, Kamari F, Sadigh-Eteghad S, Rasta SH, Hamblin MR. Brain Photobiomodulation Therapy: a Narrative Review. Mol Neurobiol. 2018;55(8):6601-6636. PubMed 
102. Morriss R, Patel S, Boutry C, et al. Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial. Lancet Psychiatry 2023. pmid:36724796 PubMed 
103. Kuyken W, Warren FC, Taylor RS et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry 2016; 73(6): 565-74. pmid:27119968 PubMed 
104. Kuyken W, Hayes R, Barrett B, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. Lancet. 2015. doi: 10.1016/S0140-6736(14)62222-4.
105. De Silva MJ, Cooper S, Li HL, et al. Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis. Br J Psychiatry. 2013 ;202(4):253-60. doi: 10.1192/bjp.bp.112.118018 DOI 
106. Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database of Syst Rev 2013; 2. DOI: 10.1002/14651858.CD001134.pub3. DOI 
107. DeRubeis RJ, Zajecka J, Shelton RC, et al. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial published correction appears in JAMA Psychiatry. 2020 Jan 29;:. JAMA Psychiatry. 2020;77(3):237-245. PubMed 
108. Bica T, Castelló R, Toussaint LL, Montesó-Curto P. Depression as a Risk Factor of Organic Diseases:An International Integrative Review. J Nurs Scholarsh. 2017;49(4):389-399. PubMed 
109. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299-2312. PubMed 
110. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160: 3278-85. PubMed